Print Friendly, PDF & Email

NCT/Study#

NCT02628405 /

RU051417I

Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: